ARTICLE | Company News
Veloxis submits Envarsus NDA
December 31, 2013 1:07 AM UTC
Veloxis Pharmaceuticals A/S (CSE:VELO) submitted an NDA to FDA for Envarsus tacrolimus (formerly LCP-Tacro) to prevent organ rejection in kidney transplant patients. An MAA for the product is under re...